Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353420 | 0.90 | KDM4E (0.56) | RAB9ALMNAKMT2ACYP1A2HDAC1 | |
| SCHEMBL1351176 | 0.89 | KCNK3 (0.55) | RAB9ALMNASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL1352789 | 0.88 | CHEK1 (0.58) | RAB9ALMNAKMT2ACYP1A2HDAC1 | |
| SCHEMBL1351225 | 0.88 | PDE4D (0.57) | RAB9ALMNASMN1; SMN2KMT2ACYP1A2 | |
| SCHEMBL1354395 | 0.88 | PDE4D (0.70) | RAB9ALMNAKMT2ACYP1A2HDAC1 | |
| SCHEMBL1353055 | 0.87 | TSHR (0.68) | RAB9ALMNASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL1351165 | 0.86 | ALDH1A1 (0.64) | RAB9ALMNASMN1; SMN2KMT2ACYP1A2 | |
| SCHEMBL1353257 | 0.85 | TP53 (0.68) | RAB9ALMNASMN1; SMN2KMT2ACYP1A2 | |
| SCHEMBL1353007 | 0.84 | SMN1; SMN2 (0.66) | RAB9ALMNASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL1353162 | 0.84 | PDE4D (0.57) | RAB9ALMNASMN1; SMN2KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-1698618-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1698618-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123493-A1 | Benzamide derivative | BDKRB1, BDKRB2, NR1H2 | RAB9A 2244/4885LMNA 2100/4885SMN1; SMN2 3867/4885 |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | NR0B2, NR1H2, CNR2 | RAB9A 2884/4885LMNA 1833/4885SMN1; SMN2 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.